Theravance Biopharma Inc (0TB) - Total Assets
Based on the latest financial reports, Theravance Biopharma Inc (0TB) holds total assets worth €415.46 Million EUR (≈ $485.72 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Theravance Biopharma Inc (0TB) shareholders funds for net asset value and shareholders' equity analysis.
Theravance Biopharma Inc - Total Assets Trend (2014–2024)
This chart illustrates how Theravance Biopharma Inc's total assets have evolved over time, based on quarterly financial data.
Theravance Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Theravance Biopharma Inc's total assets of €415.46 Million consist of 45.5% current assets and 54.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.7% |
| Accounts Receivable | €18.44 Million | 5.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Theravance Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 0TB market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theravance Biopharma Inc's current assets represent 45.5% of total assets in 2024, a decrease from 81.5% in 2014.
- Cash Position: Cash and equivalents constituted 10.7% of total assets in 2024, down from 26.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 5.2% of total assets.
Theravance Biopharma Inc Competitors by Total Assets
Key competitors of Theravance Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Theravance Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.48 | 4.97 | 3.18 |
| Quick Ratio | 9.48 | 4.97 | 3.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €317.29 Million | €93.05 Million | €269.77 Million |
Theravance Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Theravance Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.21 |
| Latest Market Cap to Assets Ratio | 2.34 |
| Asset Growth Rate (YoY) | -7.3% |
| Total Assets | €354.16 Million |
| Market Capitalization | $828.57 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Theravance Biopharma Inc's assets at a significant premium (2.34x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Theravance Biopharma Inc's assets decreased by 7.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Theravance Biopharma Inc (2014–2024)
The table below shows the annual total assets of Theravance Biopharma Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €354.16 Million ≈ $414.05 Million |
-7.29% |
| 2023-12-31 | €382.00 Million ≈ $446.60 Million |
-37.11% |
| 2022-12-31 | €607.40 Million ≈ $710.11 Million |
+62.05% |
| 2021-12-31 | €374.82 Million ≈ $438.20 Million |
-20.09% |
| 2020-12-31 | €469.06 Million ≈ $548.38 Million |
+14.73% |
| 2019-12-31 | €408.83 Million ≈ $477.96 Million |
-27.03% |
| 2018-12-31 | €560.24 Million ≈ $654.97 Million |
+26.92% |
| 2017-12-31 | €441.40 Million ≈ $516.04 Million |
-30.95% |
| 2016-12-31 | €639.25 Million ≈ $747.36 Million |
+113.00% |
| 2015-12-31 | €300.12 Million ≈ $350.87 Million |
-11.15% |
| 2014-12-31 | €337.77 Million ≈ $394.89 Million |
-- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more